{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-198580","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.331563+00:00","generated_at":"2026-06-12T22:13:14.824225+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Taysha Gene Therapies gets IDMC nod to continue REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome","bullets":["IDMC recommended trial continuation after review of initial clinical data from first adult dosed with TSHA-102.","Dosing of second patient expected in Q3 2023.","Initial clinical update on first patient planned for Q2 2023 earnings call in mid-August.","TSHA-102 is an AAV-based gene therapy for Rett syndrome due to MECP2 loss-of-function mutation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-198580","json":"https://secwatch.observer/filing/0001193125-23-198580.json","markdown":"https://secwatch.observer/filing/0001193125-23-198580.md","text":"https://secwatch.observer/filing/0001193125-23-198580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523198580/0001193125-23-198580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523198580/d535611d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T22:13:14.824225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}